Merck’s RSV antibody treatment for infants is approved by FDA
The simplicity of Merck’s monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca’s existing treatment.
Related Articles
A vaccine expert explains why she’s ‘very worried’ about RFK Jr. and new CDC vaccine advisers
A conversation with Kathryn Edwards, a physician and expert in childhood respiratory diseases and vaccine safety, on RFK Jr.’s latest ACIP shakeup.
Pharma wins a victory over a Minnesota law designed to provide transparency into drug pricing
Once again, pharma fends off an effort by a state to impose more transparency on drug pricing.
The upheaval of CDC’s vaccine panel, and drug pricing confusion
This week on “The Readout LOUD”: Why did RFK Jr. abruptly fire all members of CDC’s vaccine advisory panel? Vaccine expert Kathryn Edwards joins the…
How physicians like me are grappling with requests for unvaccinated donor blood
As a transfusion medicine physician, Jeremy W. Jacobs has increasingly faced requests for “unvaccinated donor blood.” So he and colleagues looked closer at what the…
Medicare Advantage’s supplemental benefits will cost taxpayers $86 billion this year, with little transparency
Taxpayers will send an estimated $86 billion to Medicare Advantage insurers this year to pay for supplemental benefits for their members, or 17% of total
A closer look at the new members of the CDC vaccine advisory panel
For more than a half-century, the Centers for Disease Control and Prevention have relied on outside experts to guide the agency’s recommendations on how
How physicians like me are grappling with requests for unvaccinated donor blood
As a transfusion medicine physician, Jeremy W. Jacobs has increasingly faced requests for “unvaccinated donor blood.” So he and colleagues looked closer at what the…
FDA clears Moderna’s RSV vaccine for use in people aged 18 to 59
The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a welcome win.
FDA clears Moderna’s RSV vaccine for use in people aged 18 to 59
The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a welcome win.
BioNTech to buy CureVac in $1.25 billion deal, saying it will bolster cancer work
BioNTech said Thursday it would buy CureVac, its onetime competitor in the Covid-19 vaccine race, for about $1.25 billion in an all-stock transaction.